Market Performance
- Dr Reddy’s Laboratories (DRL) surged 4% to ₹1,303 on June 5, becoming the top gainer on the Nifty 50.
- The stock has climbed 9% over the past month, sharply outpacing the Nifty 50’s modest 1% rise.
Key Driver: Biosimilar Partnership with Alvotech
Dr Reddy’s Lab announced a strategic collaboration with Alvotech to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab)—a leading cancer immunotherapy drug.
Why This Deal Matters
- Keytruda’s global sales reached $29.5 billion in 2024, making it one of the top-selling drugs worldwide.
- The partnership combines Alvotech’s biosimilar expertise and Dr. Reddy’s global reach, accelerating development and commercialization.
- Both companies will share costs, manufacturing, and marketing rights in most international markets.
Growth Outlook & Earnings Drivers
- Semaglutide (diabetes drug) is expected to boost earnings in Canada, Brazil, and India due to high demand and limited supply.
- Unlike typical generics, prices may remain stable, leading to strong revenue growth.
Summary
Dr Reddy’s Lab share price surged 4% after signing a major biosimilar deal with Alvotech for Keytruda, a blockbuster cancer drug.
